Quest Diagnostics' Sonora Quest Laboratories Welcomes New CEO Jennifer Erickson Amid Growth
- Jennifer Erickson will succeed David Dexter as CEO of Sonora Quest Laboratories, effective March 31, 2026.
- Under Dexter, Sonora Quest became Arizona's top clinical laboratory, processing over 100 million tests annually.
- The company is focused on enhancing diagnostic services and exploring new technologies to improve patient access.
Leadership Transition Signals Continued Growth at Sonora Quest Laboratories
Sonora Quest Laboratories announces the appointment of Jennifer Erickson as Chief Executive Officer-Elect, set to succeed David Dexter, who will retire on March 31, 2026, after a remarkable tenure of over 26 years. Under Dexter's leadership since 1999, Sonora Quest has emerged as Arizona's leading clinical laboratory testing provider, processing more than 100 million diagnostic tests annually. His era is marked by significant advancements, including the launch of the direct-access testing platform, My Lab ReQuest™, in 2015, and the pivotal expansion of COVID-19 testing through Operation Catapult in 2020. These initiatives not only enhanced the company's testing capabilities but also demonstrated its commitment to accessible healthcare during a global crisis.
Erickson brings a wealth of experience to her new role, having spent over 20 years in the healthcare and consumer services sectors. Notably, she served as the Chief Financial Officer at Sonora Quest from 1999 to 2004, giving her a deep understanding of the company’s operations and strategic goals. This familiarity, coupled with her recent position as CFO and COO at Clin-Path Associates/Pathology Specialists of Arizona, positions her well to continue the legacy of growth and innovation that Dexter has cultivated. As she steps into the CEO role, Erickson is committed to advancing patient-centered diagnostics and enhancing partnerships within the healthcare community, ensuring that Sonora Quest remains at the forefront of laboratory services.
David Dexter's mentorship of Erickson over the past 26 years underscores a strong continuity in leadership philosophy at Sonora Quest. Dexter emphasizes that Erickson embodies the company’s culture of collaboration and accountability—qualities that will be essential as the organization navigates the evolving landscape of healthcare. With a focus on innovation, Erickson aims to build upon Dexter's successful initiatives while addressing emerging challenges and opportunities within the industry.
In other relevant developments, Sonora Quest continues to strengthen its position in the diagnostics market by exploring new technologies and partnerships that enhance service delivery. The company is actively engaged in discussions with various healthcare providers to expand its testing capabilities, thereby improving patient access to essential diagnostic services. As the healthcare landscape evolves, Sonora Quest’s strategic initiatives reflect its commitment to leading the industry in quality and innovation.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

